Aphaia Pharma to Participate in a Panel Discussion at the 1st Annual Obesity & Metabolic Innovation Forum
ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, November 25, 2024 – Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 1st Annual Obesity & Metabolic Innovation Forum, taking place December 4, 2024, in Boston, Massachusetts.